ClinicalTrials.gg
CompletedNCT03442725Updated Apr 8, 2020Results posted

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

A Phase 1 interventional study of Telotristat etiprate in Renal Impairment, sponsored by Ipsen. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Ipsen · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 33 studies in Renal Insufficiency with a site in Belgium — 4 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency · Belgium.

Enrollment
20th of 23
16 · median 117
Started
2018
with 3 others
Phase 1
3 of 33
none open now
Registered
26th of 33
by date

Among the 33 studies in Renal Insufficiency with a site in Belgium, this one is the 20th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 1, and was the 26th registered.

Renal Insufficiency

1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

4 of the 33 studies in Renal Insufficiency with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Renal Insufficiency with a site in Belgium, or all of them as a file.
02

Study summary

Renal excretion is a minor elimination route of telotristat etiprate. So this trial is intended to assess the drug behaviour in subjects with decreased renal function.

This is a staged study with Part B contingent upon the results of Part A. Part A will enrol a total of 16 subjects, eight with severely impaired renal function and eight healthy subjects. Part B with enrol a total of 16 subjects, eight subjects in each additional renal function group, i.e. mildly impaired renal function group and moderately impaired group.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  • Provision of written prior to any study related procedure.
  • Men and women enrolling in the study must be at least 18 years of age at the time of giving informed consent.
  • Women of must agree to use an adequate double-barrier method of during the study and for 30 days after discharge.
  • Men must agree to use an adequate, double barrier method of contraception during the study and for 30 days after discharge.

Additionally, for subjects with renal impaired function:

  • Clinical diagnosis of renal impaired function that has been stable for more than 3 months prior to dosing
  • Renal impaired function classified as mild, moderate, or severe.
  • Under stable medication regimen, i.e. not starting new therapy(ies) or significant changing dosage(s) within at least 1 month prior to dosing, as determined by the investigator.
  • Stable and appropriately managed relative to chronic diseases (e.g. diabetes, hypertension) as determined by medical history, physical examination, ECGs, and clinical laboratory tests.

Additionally, for healthy subjects with normal renal function:

  • Each subject will be demographically-matched to one of the subjects with severely impaired renal function for gender, age (± 10 years), (± 20%).
  • Clinical laboratory test results must be strictly within the normal laboratory reference ranges for urea, creatinine, protein, and albumin.

Exclusion criteria

Exclusion Criteria:

All subjects:

  • Existence of any surgical or medical condition that, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism, or excretion of telotristat etiprate (including bariatric surgery, or any other gastrointestinal surgery, excepting appendectomy and hernia repair, which are acceptable).
  • History of any major surgery within six months or anticipated surgery prior to Day-1.
  • Patients with hereditary problems of galactose intolerance (lactase deficiency or glucose-galactose malabsorption).
  • History of any active infection within 30 days prior to Day-1, if deemed by the investigator.
  • Positive hepatitis panel results (including surface antigen and hepatitis virus C ribonucleic acid).
  • Positive results for , or who has received diagnosis for acquired immunodeficiency syndrome.
  • Positive urine screen for drugs of abuse (not including cotinine).
  • Consumption of alcohol within 48 hours prior to Day-1 (as confirmed by alcohol breath screen) and for the duration of the confinement period.
  • Smoking more than ten cigarettes per day or equivalent; unable or unwilling to refrain from smoking and tobacco use for two hours prior to dosing and four hours after dose administration.
  • Consumption of caffeine- and/or xanthine-containing products (e.g. cola, coffee, tea, chocolate) on Day-1 until 24 hours postdose.
  • Consumption of grapefruit, Seville oranges, and grapefruit- or Seville orange-containing products within 72 hours prior to Day-1 and for the duration of the confinement period.
  • Use of any medication (prescription or over-the-counter), Chinese herbal medications or herbal tea, energy drinks, herbal products (e.g. St. John's wort, garlic), or supplements/supra therapeutic doses of vitamins within 14 days prior to Day-1 and up to Day 4 after dosing, apart from those approved by the investigator.
  • Women who are breastfeeding or are planning to become pregnant during the study.

Additionally, for renal impaired subjects:

  • Clinically significant physical (e.g. oedema in heavy subjects with renal impaired function), laboratory, or findings (apart from those parameters which are related to impaired renal function or underlying disease e.g. diabetes, hypertension) that, in the opinion of the investigator, may interfere with any aspect of the study conduct or interpretation of the results.
  • A1c ≥ 9%.

Additionally, for healthy subjects with normal renal function:

  • Clinically significant illness or disease including cardiac, pulmonary, hepato-biliary, gastrointestinal, or endocrinology, or cancer within the last 5 years (except localised or in situ non-melanoma skin cancer), as determined by medical history, physical examination, laboratory tests, and 12-lead ECGs.
  • Clinically significant physical, laboratory, or ECG findings that, in the opinion of the investigator, may interfere with any aspect of the study conduct or interpretation of the results.
  • History of renal disease.
  • History of alcohol or drug abuse within 2 years prior to screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Severely decreased renal function group

    Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).

    Drug: Telotristat etiprate

  • Active comparator
    Normal renal function group

    Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).

    Drug: Telotristat etiprate

  • Experimental
    Mildly decreased renal function group

    Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).

    Drug: Telotristat etiprate

  • Experimental
    Moderately decreased renal function group

    Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).

    Drug: Telotristat etiprate

Interventions

  • DrugTelotristat ethylStudies of Telotristat ethylTelotristat ethyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.

    Also known as: Xermelo®

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method with a lower limit of quantitation (LOQ) of 0.5 nanograms (ng)/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Cmax was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  2. Time to Maximum Observed Plasma Concentration (Tmax) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Tmax was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  3. Apparent Terminal Elimination Half-Life (t1/2) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. T1/2 was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  4. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-inf was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  5. Area Under the Plasma Concentration-Time Curve From Time 0 to Time Corresponding to the Last Quantifiable Concentration (AUC0-tlast) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-tlast was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  6. Apparent First Order Terminal Elimination Rate Constant (λz) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. λz was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  7. Apparent Total Clearance From Plasma (CL/F) of Total Telotristat Ethyl

    Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. CL/F was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  8. Apparent Volume of Distribution (Vd/F) of Total Telotristat Ethyl

    Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. Vd/F was determined using non-compartmental analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

  9. Percentage of Unbound Plasma Fraction (fu) of Total Telotristat Ethyl, LP-778902 and LP-951757

    Plasma protein binding was assessed using equilibrium dialysis followed by LC-MS/MS for determination of unbound drug concentrations. The plasma protein binding of telotristat ethyl, LP-778902 and LP-951757 was assessed and the percentage of fu was calculated as the mean over time of the mean of the available replicates.

    Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)

  10. Cmax for the Unbound Fraction (Cmaxu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757

    Cmaxu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.

    Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)

  11. AUC0-inf for the Unbound Fraction (AUC0-infu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757

    AUC0-infu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.

    Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)

  12. AUC0-tlast for the Unbound Fraction (AUC0-tlastu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757

    AUC0-tlastu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.

    Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)

  13. Metabolic Ratios (MR) of Cmax (LP-778902/Telotristat Ethyl)

    The following MRs of Cmax were calculated: MRCmax = (Cmax LP-778902)/(Cmax telotristat ethyl) MRCmaxTotal = (Cmax LP-778902)/(Cmax LP-778902+Cmax telotristat ethyl) The ratios were also normalised by molecular weight (MW) of the metabolites (telotristat ethyl: MW=575 grams/mole (g/mol) and LP-778902: MW=547 g/mol). Both the normalised and not normalised ratios are presented.

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)

Secondary outcomes

  1. Amount of Unchanged Telotristat Ethyl and LP-778902 Excreted in Urine.

    For assessment of urine PK parameters, the amount of unchanged telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) excreted in urine was determined.

    Time frame: Day 1 (predose and 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, 12 to 24 hours post-dose), Day 2 (24 to 48 hours post-dose), Day 3 (48 to 72 hours post-dose)

07

Results

Posted Sep 13, 2019
Limitations and caveats
In accordance with the statistical analysis plan, PK parameters were not calculated if more than one-third of the values were BLQ at a single time point. No statistical comparisons were performed on PK parameters for LP-951757.

Participant flow

A total of 16 subjects were recruited in this open label, single dose study between February and May 2018. Recruited subjects were split evenly between 2 groups (control group and test group).

Participant flow — Overall Study
MilestoneHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Started88
Completed88
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757

Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method with a lower limit of quantitation (LOQ) of 0.5 nanograms (ng)/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Cmax was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757
ng/mLHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat Ethyl3.81 ± 98.94.94 ± 116
LP-778902533 ± 58.1759 ± 52.9
LP-95175765.2 ± 46.045.6 ± 80.2
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.297 · 90% CI 0.600 to 2.805
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.423 · 90% CI 0.901 to 2.247
PrimaryTime to Maximum Observed Plasma Concentration (Tmax) of Total Telotristat Ethyl, LP-778902 and LP-951757

Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Tmax was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Total Telotristat Ethyl, LP-778902 and LP-951757
hoursHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat Ethyl1.03 (0.500 to 3.00)1.00 (0.500 to 3.00)
LP-7789022.00 (1.00 to 4.00)2.50 (1.00 to 3.00)
LP-9517574.00 (3.00 to 8.00)4.00 (2.02 to 6.00)
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Wilcoxon (Mann-Whitney) · p = 0.7452 · Median difference: 0.000 · 90% CI -1.000 to 0.950
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Wilcoxon (Mann-Whitney) · p = 0.7039 · Median difference: 0.000 · 90% CI -1.000 to 1.000
PrimaryApparent Terminal Elimination Half-Life (t1/2) of Total Telotristat Ethyl, LP-778902 and LP-951757

Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. T1/2 was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Mean · hours
Apparent Terminal Elimination Half-Life (t1/2) of Total Telotristat Ethyl, LP-778902 and LP-951757
hoursHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789029.05 ± 3.028.31 ± 1.51
LP-95175711.5 ± 4.659.93 ± 4.45
PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Total Telotristat Ethyl, LP-778902 and LP-951757

Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-inf was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Geometric mean · ng*hour/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Total Telotristat Ethyl, LP-778902 and LP-951757
ng*hour/mLHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789021652 ± 42.72488 ± 77.9
LP-951757876 ± 66.0511 ± 115
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.506 · 90% CI 0.914 to 2.480
PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to Time Corresponding to the Last Quantifiable Concentration (AUC0-tlast) of Total Telotristat Ethyl, LP-778902 and LP-951757

Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-tlast was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Geometric mean · ng*hour/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Time Corresponding to the Last Quantifiable Concentration (AUC0-tlast) of Total Telotristat Ethyl, LP-778902 and LP-951757
ng*hour/mLHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789021637 ± 43.32475 ± 78.3
LP-951757845 ± 64.4494 ± 118
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.512 · 90% CI 0.915 to 2.498
PrimaryApparent First Order Terminal Elimination Rate Constant (λz) of Total Telotristat Ethyl, LP-778902 and LP-951757

Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. λz was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Mean · hour^-1
Apparent First Order Terminal Elimination Rate Constant (λz) of Total Telotristat Ethyl, LP-778902 and LP-951757
hour^-1Healthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789020.0890 ± 0.04690.0871 ± 0.0236
LP-9517570.0686 ± 0.02380.0821 ± 0.0381
PrimaryApparent Total Clearance From Plasma (CL/F) of Total Telotristat Ethyl

Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. CL/F was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Mean · Litres/hour
Apparent Total Clearance From Plasma (CL/F) of Total Telotristat Ethyl
Litres/hourHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Apparent Total Clearance From Plasma (CL/F) of Total Telotristat EthylNA ± NANA ± NA
PrimaryApparent Volume of Distribution (Vd/F) of Total Telotristat Ethyl

Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. Vd/F was determined using non-compartmental analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Mean · Litres
Apparent Volume of Distribution (Vd/F) of Total Telotristat Ethyl
LitresHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Apparent Volume of Distribution (Vd/F) of Total Telotristat EthylNA ± NANA ± NA
PrimaryPercentage of Unbound Plasma Fraction (fu) of Total Telotristat Ethyl, LP-778902 and LP-951757

Plasma protein binding was assessed using equilibrium dialysis followed by LC-MS/MS for determination of unbound drug concentrations. The plasma protein binding of telotristat ethyl, LP-778902 and LP-951757 was assessed and the percentage of fu was calculated as the mean over time of the mean of the available replicates.

Time frame:
Day 1 (0.5, 1, 2 and 3 hours post-dose)
Reported as:
Mean · Percentage of fu
Percentage of Unbound Plasma Fraction (fu) of Total Telotristat Ethyl, LP-778902 and LP-951757
Percentage of fuHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789020.115 ± 0.05890.134 ± 0.0524
LP-9517570.135 ± 0.2950.0608 ± 0.0923
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Arithmetic mean difference: 0.019 · 90% CI -0.030 to 0.068
PrimaryCmax for the Unbound Fraction (Cmaxu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757

Cmaxu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.

Time frame:
Day 1 (0.5, 1, 2 and 3 hours post-dose)
Reported as:
Geometric mean · ng/mL
Cmax for the Unbound Fraction (Cmaxu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757
ng/mLHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789020.554 ± 1130.957 ± 70.7
LP-9517570.0528 ± 2150.0779 ± 84.0
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.727 · 90% CI 0.866 to 3.443
PrimaryAUC0-inf for the Unbound Fraction (AUC0-infu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757

AUC0-infu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.

Time frame:
Day 1 (0.5, 1, 2 and 3 hours post-dose)
Reported as:
Geometric mean · ng*hour/mL
AUC0-inf for the Unbound Fraction (AUC0-infu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757
ng*hour/mLHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789021.72 ± 90.33.14 ± 99.2
LP-9517570.955 ± 2371.06 ± NA
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.828 · 90% CI 0.903 to 3.699
PrimaryAUC0-tlast for the Unbound Fraction (AUC0-tlastu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757

AUC0-tlastu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.

Time frame:
Day 1 (0.5, 1, 2 and 3 hours post-dose)
Reported as:
Geometric mean · ng*hour/mL
AUC0-tlast for the Unbound Fraction (AUC0-tlastu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757
ng*hour/mLHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
Telotristat EthylNA ± NANA ± NA
LP-7789021.70 ± 91.23.12 ± 99.6
LP-9517570.928 ± 2341.05 ± NA
Statistical analysis
  • Healthy Subjects (Control Group) vs Severe Renal Impairment (Test Group) · Geometric mean ratio: 1.835 · 90% CI 0.904 to 3.726
PrimaryMetabolic Ratios (MR) of Cmax (LP-778902/Telotristat Ethyl)

The following MRs of Cmax were calculated: MRCmax = (Cmax LP-778902)/(Cmax telotristat ethyl) MRCmaxTotal = (Cmax LP-778902)/(Cmax LP-778902+Cmax telotristat ethyl) The ratios were also normalised by molecular weight (MW) of the metabolites (telotristat ethyl: MW=575 grams/mole (g/mol) and LP-778902: MW=547 g/mol). Both the normalised and not normalised ratios are presented.

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Reported as:
Mean · Ratio
Metabolic Ratios (MR) of Cmax (LP-778902/Telotristat Ethyl)
RatioHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
MRCmax - not normalised154 ± 68.9204 ± 143
MRCmax - normalised162 ± 72.4215 ± 151
MRCmaxTotal - not normalised0.992 ± 0.004100.991 ± 0.00996
MRCmaxTotal - normalised0.993 ± 0.003910.991 ± 0.00949
SecondaryAmount of Unchanged Telotristat Ethyl and LP-778902 Excreted in Urine.

For assessment of urine PK parameters, the amount of unchanged telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) excreted in urine was determined.

Time frame:
Day 1 (predose and 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, 12 to 24 hours post-dose), Day 2 (24 to 48 hours post-dose), Day 3 (48 to 72 hours post-dose)
Reported as:
Mean · ng
Amount of Unchanged Telotristat Ethyl and LP-778902 Excreted in Urine.
ngHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
LP-778902: Pre-dose0 ± 00 ± 0
LP-778902: 0-4 hours post-dose88966 ± 5000319293 ± 9447
LP-778902: 4-8 hours post-dose152419 ± 4864942976 ± 22836
LP-778902: 8-12 hours post-dose173416 ± 4949947955 ± 25522
LP-778902: 12-24 hours post-dose185970 ± 4772651970 ± 27925
LP-778902: 24-48 hours post-dose191999 ± 4811053997 ± 29262
LP-778902: 48-72 hours post-dose193880 ± 4812354397 ± 29546

Adverse events

Collected over Treatment emergent adverse events were recorded from Day 1 to the end of study visit between Day 8 and Day 15 (overall timeframe: up to 15 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Subjects (Control Group)0/8 (0%)0/8 (0%)1/8 (12.5%)
Severe Renal Impairment (Test Group)0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventHealthy Subjects (Control Group)Severe Renal Impairment (Test Group)
C-reactive protein increasedInvestigations0/81/8
Heart rate increasedInvestigations0/81/8
Lymphocyte count decreasedInvestigations0/81/8
Monocyte count increasedInvestigations0/81/8
Back painMusculoskeletal and connective tissue disorders0/81/8
Muscle spasmsMusculoskeletal and connective tissue disorders0/81/8
LeukocytosisBlood and lymphatic system disorders1/80/8
NauseaGastrointestinal disorders0/81/8
ChillsGeneral disorders0/81/8
BronchitisInfections and infestations0/81/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Healthy Subjects (Control Group)Severe Renal Impairment (Test Group)Total
<=18 years000
Between 18 and 65 years7613
>=65 years123
Sex: Female, Male
Sex: Female, Male(Participants)Healthy Subjects (Control Group)Severe Renal Impairment (Test Group)Total
Female336
Male5510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy Subjects (Control Group)Severe Renal Impairment (Test Group)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8816
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Healthy Subjects (Control Group)Severe Renal Impairment (Test Group)Total
Romania336
Belgium134
Moldova202
Germany224
08

Study locations

4 sites
  • A.T.C. s.a., Clinical Pharmacology Unit, CHU Sart-Tilman
    Liège, B-4000, Belgium
  • CRS Clinical Research Services Kiel GmbH
    Kiel, D-24105, Germany
  • ARENSIA Exploratory Medicine Phase I Unit, Republican Clinical Hospital
    Chisinau, MD-2025, Moldova, Republic of
  • ARENSIA Unit in Spitalul de Nefrologie
    Bucharest, Romania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2018, 2 months.

Results were first posted in Sep 2019, 1 year 4 months after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 2 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 22, 2018
StartActual
Feb 9, 2018
Primary completionActual
Apr 27, 2018
CompletionActual
May 13, 2018
Results first posted
Sep 13, 2019
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03442725
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Feb 9, 2018
Primary completion
Apr 27, 2018
Completion
May 13, 2018
Results posted
Sep 13, 2019
Last update
Apr 8, 2020

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telotristat ethyl

Start the discussion